EB-1020 (Centanafadine) high dose

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Co., Ltd.

Conditions

Attention-Deficit Hyperactivity Disorder(ADHD)

Phase 2

A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD

RecruitingNCT07086313

Otsuka Pharmaceutical Co., Ltd.Attention-Deficit Hyperactivity Disorder(ADHD)

Start: 2025-09-03End: 2027-08-31Target: 315Updated: 2025-12-23

Phase 3

A Long-term Trial of EB-1020 in Pediatric Patients With ADHD

RecruitingNCT07087327

Otsuka Pharmaceutical Co., Ltd.Attention-Deficit Hyperactivity Disorder(ADHD)

Start: 2025-09-16End: 2027-08-31Target: 180Updated: 2025-12-23